echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jiangsu Wuzhong Trimetazidine Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate

    Jiangsu Wuzhong Trimetazidine Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 9th, Jiangsu Wuzhong issued an announcement stating that its wholly-owned subsidiary Jiangsu Wuzhong Medicine Group Co.


    Trimetazidine hydrochloride sustained-release tablets are used as an additive for the symptomatic treatment of adult patients with stable angina pectoris who are poorly controlled or unable to tolerate the first-line anti-angina pectoris treatment


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.